Synonyms: Camzyos® | MYK-461 | MYK461
mavacamten is an approved drug (FDA (2022), EMA (2023))
Compound class:
Synthetic organic
Comment: Mavacamten (MYK-461) is an orally active myosin allosteric modulator [1] that was developed by MyoKardia as a novel treatment for obstructive hypertrophic cardiomyopathy (HCM). In 2020 MyoKardia was bought by Bristol Myers Squibb. The compound interacts with both α and β cardiac myosins in vitro. Preclinical pharmacokinetics are reported in [2]. Mavacamten attenuates hypertrophic and profibrotic gene expression in rodent models of HCM [1].
|
|
Classification | |
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2022), EMA (2023)) |
IUPAC Name |
6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione |
International Nonproprietary Names | |
INN number | INN |
10492 | mavacamten |
Synonyms |
Camzyos® | MYK-461 | MYK461 |
Database Links | |
CAS Registry No. | 1642288-47-8 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL4297517 |
DrugBank Ligand | DB14921 |
GtoPdb PubChem SID | 434321700 |
PubChem CID | 117761397 |
RCSB PDB Ligand | XB2 |
Search Google for chemical match using the InChIKey | RLCLASQCAPXVLM-NSHDSACASA-N |
Search Google for chemicals with the same backbone | RLCLASQCAPXVLM |
Search PubMed clinical trials | mavacamten |
Search PubMed titles | mavacamten |
Search PubMed titles/abstracts | mavacamten |
UniChem Compound Search for chemical match using the InChIKey | RLCLASQCAPXVLM-NSHDSACASA-N |
UniChem Connectivity Search for chemical match using the InChIKey | RLCLASQCAPXVLM-NSHDSACASA-N |